Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma

Cancer Research

Volumn 72, Issue 20, 2012, Pages 5273-5284

  Girgis, Andrew H ^a   Iakovlev, Vladimir V ^a,b   Beheshti, Ben ^a   Bayani, Jane ^b,c   Squire, Jeremy A ^d   Bui, Anna ^a   Mankaruos, Marina ^a   Youssef, Youssef ^a   Khalil, Bishoy ^a   Khella, Heba ^a   Pasic, Maria ^b   Yousef, George M ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MICRORNA; MINICHROMOSOME MAINTENANCE PROTEIN 2;

ARTICLE; CA9 GENE; CANCER CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CCND1 GENE; CDKN2A GENE; CDKN2B GENE; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME 11Q; CHROMOSOME 12Q; CHROMOSOME 1P; CHROMOSOME 2Q; CHROMOSOME 3P; CHROMOSOME 3Q; CHROMOSOME 4Q; CHROMOSOME 5Q; CHROMOSOME 6Q; CHROMOSOME 7P; CHROMOSOME 7Q; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLCNKB GENE; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE EXPRESSION; GENE IDENTIFICATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; METHYLATION; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STC2 GENE; VHL GENE;

CARCINOMA, RENAL CELL; CHROMOSOME MAPPING; GENE DOSAGE; GENOME, HUMAN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KIDNEY NEOPLASMS; NUCLEIC ACID HYBRIDIZATION; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84867542519     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0656     Document Type: Article

References (49)

1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32.
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-31. (Pubitemid 29211773)
3. White NM, Yousef GM. Translating molecular signatures of renal cell carcinoma into clinical practice. J Urol 2011;186:9-11.
4. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011;108:1556-63.
5. Diamandis M, White NM, Yousef GM. Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res 2010;8:1175-87.
6. Dondeti VR, Wubbenhorst B, Lal P, Gordan JD, D'Andrea K, Attiyeh EF, et al. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res 2012;72:12-21.
7. Cifola I, Spinelli R, Beltrame L, Peano C, Fasoli E, Ferrero S, et al. Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile. Mol Cancer 2008;7:6.
8. Yoshimoto T, Matsuura K, Karnan S, Tagawa H, Nakada C, Tanigawa M, et al. High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma. J Pathol 2007;213:392-401. (Pubitemid 350206511)
9. Beroukhim R, Brunet JP, Di NA, Mertz KD, Seeley A, Pires MM, et al. Patterns of gene expression and copy-number alterations in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009;69:4674-81.
10. Chen M, Ye Y, Yang H, Tamboli P, Matin S, Tannir NM, et al. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer 2009;125:2342-8.
11. Shuib S, Wei W, Sur H, Morris MR, McMullan D, Rattenberry E, et al. Copy number profiling in von Hippel-Lindau disease renal cell carcinoma. Genes Chromosomes Cancer 2011;50:479-88.
12. Toma MI, Grosser M, Herr A, Aust DE, Meye A, Hoefling C, et al. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density Affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia 2008;10:634-42. (Pubitemid 351883879)
13. Klatte T, Rao PN, de MM, LaRochelle J, Shuch B, Zomorodian N, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009;27:746-53.
14. La RJ, Klatte T, Dastane A, Rao N, Seligson D, Said J, et al. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer 2010;116:4696-702.
15. Monzon FA, Alvarez K, Peterson L, Truong L, Amato RJ, Hernandez-McClain J, et al. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol 2011;24:1470-9.
16. Sanjmyatav J, Junker K, Matthes S, Muehr M, Sava D, Sternal M, et al. Identification of genomic alterations associated with metastasis and cancer specific survival in clear cell renal cell carcinoma. J Urol 2011;186:2078-83.
17. Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, et al. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol 2012;61:258-68.
18. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-46.
19. White NM, Bao TT, Grigull J, Youssef YM, Girgis A, Diamandis M, et al. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol 2011;186:1077-83.
20. Arsanious A, Bjarnason GA, Yousef GM. From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol Cancer 2009;8:20.
21. Siu KW, DeSouza LV, Scorilas A, Romaschin AD, Honey RJ, Stewart R, et al. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. J Proteome Res 2009;8:3797-807.
22. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007;449:851-61.
23. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72. (Pubitemid 41180205)
24. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007;104:20007-12.
25. Sanchez-Garcia F, Akavia UD, Mozes E, Pe'er D. JISTIC: identification of significant targets in cancer. BMC Bioinformatics 2010;11:189.
26. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
27. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21. (Pubitemid 32397092)
28. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
29. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res 2012;22:1197-211.
30. Faragalla H, Youssef YM, Scorilas A, Khalil B, White NM, Mejia-Guerrero S, et al. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn 2012;14:385-92.
31. White NM, Khella HW, Grigull J, Adzovic S, Youssef YM, Honey RJ, et al. miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer 2011;105:1741-9.
32. Soares MJ, Pinto M, Henrique R, Vieira J, Cerveira N, Peixoto A, et al. CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas. Mod Pathol 2009;22:744-52.
33. Minner S, Rump D, Tennstedt P, Simon R, Burandt E, Terracciano L, et al. Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer 2012;118:1268-75.
34. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439-47. (Pubitemid 39564581)
35. Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res 2008;68:2551-6. (Pubitemid 351556249)
36. Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 2002;62:3014-9. (Pubitemid 34602387)
37. Law AY, Wong CK. Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res 2010;316:466-76.
38. Meyer HA, Tolle A, Jung M, Fritzsche FR, Haendler B, Kristiansen I, et al. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol 2009;55:669-78.
39. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010;58:75-83.
40. Tang SW, Yang TC, Lin WC, Chang WH, Wang CC, Lai MK, et al. Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis 2011;32:138-45.
41. Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 2004;64:5511-7. (Pubitemid 39006576)
42. Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 2010;29:2104-17.
43. Chen YT, Tu JJ, Kao J, Zhou XK, Mazumdar M. Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. Clin Cancer Res 2005;11:6558-66. (Pubitemid 41338995)
44. Kim H, Huang W, Jiang X, Pennicooke B, Park PJ, Johnson MD. Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci U S A 2010;107:2183-8.
45. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322:1695-9.
46. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004. (Pubitemid 38327724)
47. Moeller BJ, Yordy JS, Williams MD, Giri U, Raju U, Molkentine DP, et al. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res 2011;17:2035-43.
48. Sanjmyatav J, Steiner T, Wunderlich H, Diegmann J, Gajda M, Junker K. A specific gene expression signature characterizes metastatic potential in clear cell renal cell carcinoma. J Urol 2011;186:289-94.
49. Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, et al. NFKBIA deletion in glioblastomas. N Engl J Med 2011;364:627-37.